Stanley T. Crooke
In recognition of his nearly 50 years of dedication to a novel, clinically endorsed concept of using synthetic oligonucleotides to control the expression of genes and proteins that impact disease. His singular dedication to this RNA-driven antisense platform provided a new, highly personalized pathway to resolving some of the most difficult biomedical challenges, with the ultimate potential of treating multiple infections, inflammatory conditions and cancers targeted to individual patient profiles and with minimal side-effects. Due to Dr. Crooke’s years of effort as a researcher, corporate R&D executive, biotech innovator and philanthropist, nearly a dozen antisense oligonucleotides (ASO) have been approved for clinical use since 1998; additional clinical trials focused in high unmet medical need areas like neuroscience are underway. Dr. Crooke is also recognized for his leadership in being among the first in industry to make a commitment to open science a key element of the modern R&D enterprise and to embrace the principle that even patients with the rarest of afflictions deserve the best talent and expertise our R&D industry can offer. Untold thousands of patients formerly with no hope of a cure stand to benefit from his belief in the promise of this entirely new class of medicines.